Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogenic Mesenchymal Stromal Cells in COVID-19 ARDS
NCT04615429Phase 2Completed
- Start
- Sep 2020
- Primary completion
- Jan 2022
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute respiratory distress syndrome (ARDS) and COVID-19 pneumonia (2 arms). Primary endpoint: Change in the PaO2/FiO2 Ratio at 7 days. Started Sep 2020; status: completed.
02
Conditions
acute respiratory distress syndrome (ARDS)COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04615429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04615429.